Allergan Aesthetics secures approval for Boey the first and only rapid-onset, short-duration neurotoxin for the temporary reduction of frown lines in adults

Allergan Aesthetics has recently announced that the European Commission has granted approval for Boey across Europe for the temporary improvement in the appearance of moderate to severe lines between the eyebrows at maximum frown in adult patients where these lines carry meaningful psychological impact.

The European Commission decision, reached through the centralised procedure, applies across all 30 European Economic Area countries. Boey had previously received approval in Canada in June of this year.

Boey is the first and only botulinum neurotoxin serotype E of its kind to be authorised in Europe, combining rapid onset with a short duration of effect. Clinical studies showed the onset of action appearing as early as eight hours after treatment, with results lasting between two and three weeks.

“The EU approval of Boey® marks an important step forward for our development program and builds on the momentum we’ve established with Health Canada’s approval earlier this year,” said Darin Messina, Ph.D., Senior Vice President, Aesthetics Research and Development, AbbVie. “This milestone reflects the scientific rigor behind Boey® and reinforces our commitment to advancing innovative options as we work to bring this first-of-its-kind treatment to healthcare professionals and consumers around the world.”

As demand for aesthetic treatments grows, patients are increasingly looking for options that reflect their personal goals and comfort levels. Research conducted by Allergan Aesthetics found that 80% of people are open to discovering new treatments to achieve the results they want, while 79% expressed a wish to preview the outcome of an aesthetic procedure before going ahead. Despite this appetite, many remain reluctant to take the next step, driven by uncertainty around results and an unwillingness to commit to longer-lasting changes. Boey was created with precisely these patients in mind, giving them the opportunity to experience a treatment before deciding on something more enduring.

Developed by the makers of BOTOX Cosmetic, known as VISTABEL or Vistabex in the EU, Boey adds another option for suitable patients exploring facial injectables. BOTOX Cosmetic is the only neurotoxin to have been clinically assessed for safety when used following treatment with Boey.

Allergan Aesthetics is preparing to roll out Boey across European markets and will provide healthcare professionals with education and training to support its appropriate use. The company continues to develop, manufacture, and market a broad portfolio of leading aesthetics products, maintaining a strong focus on innovation through dedicated research and development aimed at meeting the evolving needs of patients and practitioners worldwide.

---

---

Related Topics and Keywords

allergan aesthetics, neurotoxin, trenibotulinumtoxinE